Maynard Um
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $63 at Lucid Capital Markets
-
-
-
-
-
-
-
Unicycive receives patent for kidney disease drug UNI-494
-
-
-
-
-
-
-
Unicycive Therapeutics, Inc (UNCY) Announces 1:10 Reverse Share Split
-
-
-
-
-
-
-
Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Announces U.S. FDA Acceptance of the NDA for Oxylanthanum Carbonate
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Announces Submission of NDA to U.S. FDA for Oxylanthanum Carbonate for Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

